Original Article

You have full text access to this OnlineOpen article

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype†

A population-based study from the California cancer Registry

  1. Katrina R. Bauer MS CTR1,‡,*,
  2. Monica Brown PhD2,
  3. Rosemary D. Cress DrPH1,3,
  4. Carol A. Parise PhD4,
  5. Vincent Caggiano MD4,5

Article first published online: 26 MAR 2007

DOI: 10.1002/cncr.22618

Issue

Cancer

Cancer

Volume 109, Issue 9, pages 1721–1728, 1 May 2007

Additional Information

How to Cite

Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. and Caggiano, V. (2007), Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer, 109: 1721–1728. doi: 10.1002/cncr.22618

Author Information

  1. 1

    Public Health Institute/California Cancer Registry, Sacramento, California

  2. 2

    Public Health Institute/Cancer Surveillance Program, Sacramento, California

  3. 3

    Department of Health Sciences, Division of Epidemiology, UC Davis, California

  4. 4

    Sutter Institute for Medical Research, Sacramento, California

  5. 5

    Sutter Cancer Center/Cancer Surveillance Program, Sacramento, California

  1. ‡

    Fax: (916) 779-2608

*Research Associate IV, California Cancer Registry, Public Health Institute, 1700 Tribute Rd. Ste. 100, Sacramento, CA 95815-4402

  1. †

    The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Health Services, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred.

Publication History

  1. Issue published online: 18 APR 2007
  2. Article first published online: 26 MAR 2007
  3. Manuscript Accepted: 23 JAN 2007
  4. Manuscript Revised: 7 DEC 2006
  5. Manuscript Received: 26 SEP 2006

Funded by

  • California Department of Health Services
  • California Health and Safety Code Section. Grant Number: 103885
  • National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Grant Number: N01-PC-35136
  • Northern California Cancer Center. Grant Number: N01-PC-35139
  • University of Southern California. Grant Number: N02-PC-15105
  • Public Health Institute
  • Centers for Disease Control
  • Prevention's National Program of Cancer Registries. Grant Number: U55/CCR921930-02
  • Public Health Institute

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (147K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    L. Fejerman, G. K. Chen, C. Eng, S. Huntsman, D. Hu, A. Williams, B. Pasaniuc, E. M. John, M. Via, C. Gignoux, S. Ingles, K. R. Monroe, L. N. Kolonel, G. Torres-Mejia, E. J. Perez-Stable, E. Gonzalez Burchard, B. E. Henderson, C. A. Haiman, E. Ziv, Admixture mapping identifies a locus on 6q25 associated with breast cancer risk in US Latinas, Human Molecular Genetics, 2012, 21, 8, 1907

    CrossRef

  2. 2
    Volker Rudat, Hamdan El-Sweilmeen, Elias Fadel, Iris Brune-Erber, Alaa Ahmad Nour, Zinaida Bushnag, Nidal Masri, Saleh Altuwaijri, Age of 40 Years or Younger Is an Independent Risk Factor for Locoregional Failure in Early Breast Cancer: A Single-Institutional Analysis in Saudi Arabia, Journal of Oncology, 2012, 2012, 1

    CrossRef

  3. 3
    Hitomi Kurose, Masa-Aki Shibata, Munekazu Iinuma, Yoshinori Otsuki, Alterations in Cell Cycle and Induction of Apoptotic Cell Death in Breast Cancer Cells Treated with α-Mangostin Extracted from Mangosteen Pericarp, Journal of Biomedicine and Biotechnology, 2012, 2012, 1

    CrossRef

  4. 4
    Victoria Parente, Lauren Hale, Tia Palermo, Association between breast cancer and allostatic load by race: National Health and Nutrition Examination Survey 1999–2008, Psycho-Oncology, 2012, 21,
    Direct Link:
  5. 5
    L Robertson, H Hanson, S Seal, M Warren-Perry, D Hughes, I Howell, C Turnbull, R Houlston, S Shanley, S Butler, D G Evans, G Ross, D Eccles, A Tutt, N Rahman, BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years, British Journal of Cancer, 2012, 106, 6, 1234

    CrossRef

  6. 6
    Onur BaÅŸer, Wenhui Wei, Henry J. Henk, April Teitelbaum, Lin Xie, Burden of Early-Stage Triple-Negative Breast Cancer in a US Managed Care Plan, Health Outcomes Research in Medicine, 2012,

    CrossRef

  7. 7
    David J. Hiller, Quyen D. Chu, Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer, International Journal of Breast Cancer, 2012, 2012, 1

    CrossRef

  8. 8
    Neil K. Taunk, Sharad Goyal, Hao Wu, Meena S. Moran, Sining Chen, Bruce G. Haffty, DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer, Cancer, 2012, 118, 4
    Direct Link:
  9. 9
    Carol A. Parise, Katrina R. Bauer, Vincent Caggiano, Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California, Cancer, 2012, 118, 9
    Direct Link:
  10. 10
    Garth H. Rauscher, Kristi L. Allgood, Steve Whitman, Emily Conant, Disparities in Screening Mammography Services by Race/Ethnicity and Health Insurance, Journal of Women's Health, 2012, 21, 2, 154

    CrossRef

  11. 11
    Jörg B. Engel, Theresa Martens, Jens C. Hahne, Sebastian F.M. Häusler, Mathias Krockenberger, Sabine Segerer, Antonia Djakovic, Susanne Meyer, Johannes Dietl, Jörg Wischhusen, Arnd Honig, Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro, Anti-Cancer Drugs, 2012, 23, 4, 426

    CrossRef

  12. 12
    Faruk Tas, Factors Influencing the Hormone Receptor and HER2 Levels in Breast Cancer: A Population-Based Analysis, Onkologie, 2012, 35, 3, 95

    CrossRef

  13. 13
    Alice Y. Ho, Gaorav Gupta, Tari A. King, Carmen A. Perez, Sujata M. Patil, Katherine H. Rogers, Yong Hannah Wen, Edi Brogi, Monica Morrow, Clifford A. Hudis, Tiffany Traina, Beryl McCormick, Simon N. Powell, Mark E. Robson, Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy, Cancer, 2012, 118, 11
    Direct Link:
  14. 14
    Shizuka Akashi, Hiroko Kuwabara, Yoshitaka Kurisu, Yuko Takahashi, Emi Yasuda, Atsushi Takeshita, Sachie Ishizaki, Motomu Tsuji, Yuro Shibayama, Fine-needle aspiration cytology of triple-negative basal-like breast cancer, Diagnostic Cytopathology, 2012, 40, S1
    Direct Link:
  15. 15
    Nirmala Bhoo Pathy, Cuno S.P.M. Uiterwaal, Nur Aishah Taib, Helena M. Verkooijen, Cheng Har Yip, Gradually implemented new biomarkers for prognostication of breast cancer: complete case analysis may introduce bias, Journal of Clinical Epidemiology, 2012, 65, 5, 568

    CrossRef

  16. 16
    K. Kumar S, N. Gupta, A. Rajwanshi, K. Joshi, G. Singh, Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma, Cytopathology, 2012, 23, 3
    Direct Link:
  17. 17
    Kanwal P. S. Raghav, Leonel F. Hernandez-Aya, Xiudong Lei, Marianan Chavez-MacGregor, Funda Meric-Bernstam, Thomas A. Buchholz, Aysegul Sahin, Kim-Anh Do, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo, Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers, Cancer, 2012, 118, 6
    Direct Link:
  18. 18
    Ida Johansson, Kristina E. Aaltonen, Anna Ebbesson, Dorthe Grabau, Caroline Wigerup, Ingrid Hedenfalk, Lisa Rydén, Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis, Genes, Chromosomes and Cancer, 2012, 51, 4
    Direct Link:
  19. 19
    Yoshimi Arima, Naoki Hayashi, Hidemi Hayashi, Mikako Sasaki, Kazuharu Kai, Eiji Sugihara, Eriko Abe, Atsushi Yoshida, Shuji Mikami, Seigo Nakamura, Hideyuki Saya, Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer, International Journal of Cancer, 2012, 130, 11
    Direct Link:
  20. 20
    Sofia D. Merajver, Rajesh Balkrishnan, Making the case for integrated assessments of the biological, social, and system determinants of treatment for breast cancer to understand and improve outcomes in patients everywhere, Current Medical Research and Opinion, 2012, 28, 3, 415

    CrossRef

  21. 21
    Andrew A. Davis, Virginia G. Kaklamani, Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm, International Journal of Breast Cancer, 2012, 2012, 1

    CrossRef

  22. 22
    Kentaro Tamaki, Takanori Ishida, Minoru Miyashita, Masakazu Amari, Naoko Mori, Noriaki Ohuchi, Nobumitsu Tamaki, Hironobu Sasano, Multidetector row helical computed tomography for invasive ductal carcinoma of the breast: Correlation between radiological findings and the corresponding biological characteristics of patients, Cancer Science, 2012, 103, 1
    Direct Link:
  23. 23
    D. Horiuchi, L. Kusdra, N. E. Huskey, S. Chandriani, M. E. Lenburg, A. M. Gonzalez-Angulo, K. J. Creasman, A. V. Bazarov, J. W. Smyth, S. E. Davis, P. Yaswen, G. B. Mills, L. J. Esserman, A. Goga, MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition, Journal of Experimental Medicine, 2012, 209, 4, 679

    CrossRef

  24. 24
    Onur Baser, Wenhui Wei, Henry J. Henk, April Teitelbaum, Lin Xie, Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry, Current Medical Research and Opinion, 2012, 28, 3, 419

    CrossRef

  25. 25
    Florentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou, Maroulio Pertesi, Eleni Timotheadou, Alexandra V. Stavropoulou, Stavros Glentis, Evangelos Bournakis, Mattheos Bobos, Dimitrios Pectasides, Pavlos Papakostas, George Pentheroudakis, Helen Gogas, Pantelis Skarlos, Epaminontas Samantas, Dimitrios Bafaloukos, Paris A. Kosmidis, Angelos Koutras, Drakoulis Yannoukakos, Irene Konstantopoulou, George Fountzilas, Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study, Breast Cancer Research and Treatment, 2012,

    CrossRef

  26. 26
    A.J.F. Matos, C.S. Baptista, M.F. Gärtner, G.R. Rutteman, Prognostic studies of canine and feline mammary tumours: The need for standardized procedures, The Veterinary Journal, 2012,

    CrossRef

  27. 27
    Keith A. Dookeran, James J. Dignam, Nathaniel Holloway, Karen Ferrer, Marin Sekosan, Worta McCaskill-Stevens, Sarah Gehlert, Race and the Prognostic Influence of p53 in Women with Breast Cancer, Annals of Surgical Oncology, 2012,

    CrossRef

  28. 28
    Gábor Rubovszky, Zsolt Horváth, Erika Tóth, István Láng, Miklós Kásler, Significance of Histomorphology of Early Triple-Negative Breast Cancer, Pathology & Oncology Research, 2012,

    CrossRef

  29. 29
    Luke J. Peppone, Aaron S. Rickles, Michelle C. Janelsins, Michael R. Insalaco, Kristin A. Skinner, The Association Between Breast Cancer Prognostic Indicators and Serum 25-OH Vitamin D Levels, Annals of Surgical Oncology, 2012,

    CrossRef

  30. 30
    Chunfang Hao, Sen Wei, Zhongsheng Tong, Shufen Li, Yehui Shi, Xiaorui Wang, Zhi-hua Zhu, The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro, Tumor Biology, 2012,

    CrossRef

  31. 31
    Jyothi S. Prabhu, Kanu Wahi, Aruna Korlimarla, Marjorrie Correa, Suraj Manjunath, N. Raman, B. S. Srinath, T. S. Sridhar, The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women, Tumor Biology, 2012, 33, 2, 315

    CrossRef

  32. 32
    Monica Fornier, Pierre Fumoleau, The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment, The Breast Journal, 2012, 18, 1
    Direct Link:
  33. 33
    A.M. Moorman, R. Vink, H.J. Heijmans, J. van der Palen, E.A. Kouwenhoven, The prognostic value of tumour-stroma ratio in triple-negative breast cancer, European Journal of Surgical Oncology (EJSO), 2012, 38, 4, 307

    CrossRef

  34. 34
    Jeyanthy Eswaran, Dinesh Cyanam, Prakriti Mudvari, Sirigiri Divijendra Natha Reddy, Suresh B. Pakala, Sujit S. Nair, Liliana Florea, Suzanne A. W. Fuqua, Sucheta Godbole, Rakesh Kumar, Transcriptomic landscape of breast cancers through mRNA sequencing, Scientific Reports, 2012, 2,

    CrossRef

  35. 35
    Shirin Sioshansi, Shahrzad Ehdaivand, Christina Cramer, Michele. M. Lomme, Lori Lyn Price, David E. Wazer, Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy, Cancer, 2012, 118, 11
    Direct Link:
  36. 36
    Dina Kandil, Ashraf Khan, Triple negative breast carcinoma: the good, the bad and the ugly, Diagnostic Histopathology, 2012,

    CrossRef

  37. 37
    Trupti Paranjape, Helen Heneghan, Robert Lindner, Florence K Keane, Aaron Hoffman, Antoinette Hollestelle, Jemima Dorairaj, Kimberly Geyda, Cory Pelletier, Sunitha Nallur, John WM Martens, Maartje J Hooning, Michael Kerin, Daniel Zelterman, Yong Zhu, David Tuck, Lyndsay Harris, Nicola Miller, Frank Slack, Joanne Weidhaas, A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis, The Lancet Oncology, 2011, 12, 4, 377

    CrossRef

  38. 38
    Krystal R. Sexton, Luisa Franzini, R. Sue Day, Abenaa Brewster, Sally W. Vernon, Melissa L. Bondy, A review of body size and breast cancer risk in Hispanic and African American women, Cancer, 2011, 117, 23
    Direct Link:
  39. 39
    Shinichiro Kashiwagi, Masakazu Yashiro, Tsutomu Takashima, Naoki Aomatsu, Katsumi Ikeda, Yoshinari Ogawa, Tetsuro Ishikawa, Kosei Hirakawa, Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67, Breast Cancer Research, 2011, 13, 6, R122

    CrossRef

  40. 40
    Antje Schubert, Thomas Hawighorst, Günter Emons, Carsten Gründker, Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo, Breast Cancer Research and Treatment, 2011, 130, 3, 783

    CrossRef

  41. 41
    Rita Nanda, “Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers, Seminars in Oncology, 2011, 38, 2, 254

    CrossRef

  42. 42
    Anastasia Pazaiti, Ian S Fentiman, Basal phenotype breast cancer: implications for treatment and prognosis, Women's Health, 2011, 7, 2, 181

    CrossRef

  43. 43
    Richard R. Drake, Lisa H. Cazares, E. Ellen Jones, Thomas W. Fuller, O. John Semmes, Christine Laronga, Challenges to Developing Proteomic-Based Breast Cancer Diagnostics, OMICS: A Journal of Integrative Biology, 2011, 15, 5, 251

    CrossRef

  44. 44
    Shusen Wang, Yanxia Shi, Zhongyu Yuan, Xi Wang, Donggen Liu, Roujun Peng, Xiaoyu Teng, Tao Qin, Jiewen Peng, Guinan Lin, Xiaomei Jiang, Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens, Medical Oncology, 2011,

    CrossRef

  45. 45
    J.-H. Chen, R.S. Mehta, H.-M. Baek, K. Nie, H. Liu, M.Q. Lin, H.J. Yu, O. Nalcioglu, M.-Y. Su, Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS, NMR in Biomedicine, 2011, 24, 3
    Direct Link:
  46. 46
    Jun Tang, Chu-Cheng Wu, Ze-Ming Xie, Rong-Zhen Luo, Ming-Tian Yang, Comparison of Clinical Features and Treatment Outcome of Breast Cancers in Young and Elderly Chinese Patients, Breast Care, 2011, 6, 6, 435

    CrossRef

  47. 47
    Kentaro Tamaki, Takanori Ishida, Minoru Miyashita, Masakazu Amari, Noriaki Ohuchi, Nobumitsu Tamaki, Hironobu Sasano, Correlation between mammographic findings and corresponding histopathology: Potential predictors for biological characteristics of breast diseases, Cancer Science, 2011, 102, 12
    Direct Link:
  48. 48
    Jan T. Lowery, Tim Byers, John Kittelson, John E. Hokanson, Judy Mouchawar, John Lewin, Dan Merrick, Lisa Hines, Meenakshi Singh, Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?, Breast Cancer Research and Treatment, 2011, 129, 1, 211

    CrossRef

  49. 49
    Donggen Liu, Jiehua He, Zhongyu Yuan, Shusen Wang, Roujun Peng, Yanxia Shi, Xiaoyu Teng, Tao Qin, EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray, Medical Oncology, 2011,

    CrossRef

  50. 50
    Rita A. Mukhtar, Amy P. Moore, Onouwem Nseyo, Frederick L. Baehner, Alfred Au, Dan H. Moore, Patrick Twomey, Michael J. Campbell, Laura J. Esserman, Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity, Breast Cancer Research and Treatment, 2011, 130, 2, 635

    CrossRef

  51. 51
    Gertraud Maskarinec, Cherisse Sen, Karin Koga, Shannon M Conroy, Ethnic differences in breast cancer survival: status and determinants, Women's Health, 2011, 7, 6, 677

    CrossRef

  52. 52
    Lisa M. Hines, Betsy Risendal, Tim Byers, Sarah Mengshol, Jan Lowery, Meenakshi Singh, Ethnic Disparities in Breast Tumor Phenotypic Subtypes in Hispanic and Non-Hispanic White Women, Journal of Women's Health, 2011, 20, 10, 1543

    CrossRef

  53. 53
    Adele Caldarella, Emanuele Crocetti, Simonetta Bianchi, Vania Vezzosi, Carmelo Urso, Mauro Biancalani, Marco Zappa, Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis, Pathology & Oncology Research, 2011, 17, 3, 753

    CrossRef

  54. 54
    Lenora W. M. Loo, Yinghui Wang, Erin M. Flynn, Mary Jo Lund, Erin J. Aiello Bowles, Diana S. M. Buist, Jonathan M. Liff, Elaine W. Flagg, Ralph J. Coates, J. William Eley, Li Hsu, Peggy L. Porter, Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women, Breast Cancer Research and Treatment, 2011, 127, 1, 297

    CrossRef

  55. 55
    Virginia G Kaklamani, Binge H Xu, Henry L Gomez, Global experience with ixabepilone in breast cancer, Expert Review of Anticancer Therapy, 2011, 11, 5, 683

    CrossRef

  56. 56
    Marta Cuadros, Carlos Cano, Francisco Javier López, Paloma Talavera, Inmaculada García-Peréz, Armando Blanco, Ángel Concha, HER2 status in breast cancer: experience of a Spanish National Reference Centre, Clinical and Translational Oncology, 2011, 13, 5, 335

    CrossRef

  57. 57
    Kathryn C. Amirikia, Paul Mills, Jason Bush, Lisa A Newman, Higher population-based incidence rates of triple-negative breast cancer among young African-American women , Cancer, 2011, 117, 12
    Direct Link:
  58. 58
    Christos Vaklavas, Andres Forero-Torres, How do I Treat “Triple-Negative” Disease, Current Treatment Options in Oncology, 2011, 12, 4, 369

    CrossRef

  59. 59
    Layla Parast, Su-Chun Cheng, Tianxi Cai, Incorporating short-term outcome information to predict long-term survival with discrete markers, Biometrical Journal, 2011, 53, 2
    Direct Link:
  60. 60
    Jayeon Kim, Kutluk Oktay, Infertility as a risk factor of ovarian and breast cancer, Expert Review of Obstetrics & Gynecology, 2011, 6, 2, 153

    CrossRef

  61. You have free access to this content61
    Hongchao Shan, Tetsuyuki Takahashi, Yoshimi Bando, Keisuke Izumi, Hisanori Uehara, Inhibitory effect of soluble platelet-derived growth factor receptor β on intraosseous growth of breast cancer cells in nude mice, Cancer Science, 2011, 102, 10
    Direct Link:
  62. 62
    T. A. Wallace, D. N. Martin, S. Ambs, Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale, Carcinogenesis, 2011, 32, 8, 1107

    CrossRef

  63. 63
    Lluis Catasus, Alberto Gallardo, Vicenta Llorente-Cortes, Daniel Escuin, Josefina Muñoz, Ariadna Tibau, Gloria Peiro, Agusti Barnadas, Enrique Lerma, Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/neu and triple-negative breast carcinomas, Human Pathology, 2011, 42, 11, 1581

    CrossRef

  64. 64
    Yurdanur Sullu, Guzin G. Demirag, Arzu Yildirim, Filiz Karagoz, Bedri Kandemir, Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast, Pathology - Research and Practice, 2011, 207, 12, 747

    CrossRef

  65. 65
    Tatsunari Sasada, Shigeru Murakami, Tsuyoshi Kataoka, Masahiro Ohara, Shinji Ozaki, Morihito Okada, Hideki Ohdan, Memorial Sloan-Kettering Cancer Center Nomogram to predict the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients, Surgery Today, 2011, 42, 3, 245

    CrossRef

  66. 66
    Xin Yao, Han Hao, Yanda Li, Shao Li, Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network, BMC Systems Biology, 2011, 5, 1, 79

    CrossRef

  67. 67
    Yvonne Hui-Fang Teng, Wai-Jin Tan, Aye-Aye Thike, Poh-Yian Cheok, Gary Man-Kit Tse, Nan-Soon Wong, George Wai-Cheong Yip, Boon-Huat Bay, Puay-Hoon Tan, Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy, Breast Cancer Research, 2011, 13, 2, R35

    CrossRef

  68. 68
    André Albergaria, Sara Ricardo, Fernanda Milanezi, Vítor Carneiro, Isabel Amendoeira, Daniella Vieira, Jorge Cameselle-Teijeiro, Fernando Schmitt, Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?, BMC Cancer, 2011, 11, 1, 299

    CrossRef

  69. 69
    Veronica I. Lagos-Jaramillo, Michael F. Press, Charité N. Ricker, Louis Dubeau, Phuong L. Mai, Jeffrey N. Weitzel, Pathological characteristics of BRCA-associated breast cancers in Hispanics, Breast Cancer Research and Treatment, 2011, 130, 1, 281

    CrossRef

  70. 70
    Renaud Sabatier, Jocelyne Jacquemier, François Bertucci, Benjamin Esterni, Pascal Finetti, Francine Azario, Daniel Birnbaum, Patrice Viens, Anthony Gonçalves, Jean-Marc Extra, Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome, European Journal of Cancer, 2011, 47, 10, 1537

    CrossRef

  71. 71
    M. -P. Chauvet, M. Debled, C. Decanter, A. Goncalves, R. Largillier, P. Pujol, P. Saltel, P. Taourel, Prise en charge du cancer du sein infiltrant de la femme âgée de 40 ans ou moins, Oncologie, 2011, 13, 10-11, 703

    CrossRef

  72. 72
    Hakan Mersin, Kaptan Gülben, Uğur Berberoğlu, Mete Yazι, Gökçe Acun, Volkan Kιnaş, Şükrü Erdoğan, Prognostic Factors Affecting Postmastectomy Locoregional Recurrence in Patients with Early Breast Cancer: Are Intrinsic Subtypes Effective?, World Journal of Surgery, 2011, 35, 10, 2196

    CrossRef

  73. 73
    Eun-Kyu Kim, Woo Chul Noh, Wonshik Han, Dong-Young Noh, Prognostic Significance of Young Age (<35 Years) by Subtype Based on ER, PR, and HER2 Status in Breast Cancer: A Nationwide Registry-Based Study, World Journal of Surgery, 2011, 35, 6, 1244

    CrossRef

  74. 74
    Jiehua He, Roujun Peng, Zhongyu Yuan, Shusen Wang, Jiewen Peng, Guinan Lin, Xiaomei Jiang, Tao Qin, Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray, Medical Oncology, 2011,

    CrossRef

  75. 75
    Ningqi Hou, Dezheng Huo, Olufunmilayo I. Olopade, Protective effect of longstanding lactation and reproductive factors: a case–control study in North Tanzania, Breast Cancer Research and Treatment, 2011,

    CrossRef

  76. 76
    Kristi D. Graves, Juleen Christopher, Toni Michelle Harrison, Beth N. Peshkin, Claudine Isaacs, Vanessa B. Sheppard, Providers’ Perceptions and Practices Regarding BRCA1/2 Genetic Counseling and Testing in African American Women, Journal of Genetic Counseling, 2011, 20, 6, 674

    CrossRef

  77. 77
    Alicia J. Morehead-Gee, Lucinda Pfalzer, Ellen Levy, Charles McGarvey, Barbara Springer, Peter Soballe, Lynn Gerber, Nicole L. Stout, Racial disparities in physical and functional domains in women with breast cancer, Supportive Care in Cancer, 2011,

    CrossRef

  78. 78
    J.L. Wright, I.M. Reis, W. Zhao, J.E. Panoff, C. Takita, V. Sujoy, C.R. Gomez, M. Jorda, D. Franceschi, J. Hurley, Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy, The Breast, 2011,

    CrossRef

  79. 79
    L. Bernstein, J. V. Lacey, Receptors, Associations, and Risk Factor Differences by Breast Cancer Subtypes: Positive or Negative?, JNCI Journal of the National Cancer Institute, 2011, 103, 6, 451

    CrossRef

  80. 80
    A. I. Phipps, R. T. Chlebowski, R. Prentice, A. McTiernan, J. Wactawski-Wende, L. H. Kuller, L. L. Adams-Campbell, D. Lane, M. L. Stefanick, M. Vitolins, G. C. Kabat, T. E. Rohan, C. I. Li, Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer, JNCI Journal of the National Cancer Institute, 2011, 103, 6, 470

    CrossRef

  81. 81
    Jiannan Wu, Shunrong Li, Weijuan Jia, Fengxi Su, Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer, Journal of Cancer Research and Clinical Oncology, 2011, 137, 10, 1505

    CrossRef

  82. 82
    Mia M. Gaudet, Michael F. Press, Robert W. Haile, Charles F. Lynch, Sally L. Glaser, Joellen Schildkraut, Marilie D. Gammon, W. Douglas Thompson, Jonine L. Bernstein, Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger, Breast Cancer Research and Treatment, 2011, 130, 2, 587

    CrossRef

  83. 83
    Geoffrey C. Kabat, Mimi Kim, Amanda I. Phipps, Christopher I. Li, Catherine R. Messina, Jean Wactawski-Wende, Lewis Kuller, Michael S. Simon, Shagufta Yasmeen, Sylvia Wassertheil-Smoller, Thomas E. Rohan, Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women, Cancer Causes & Control, 2011, 22, 5, 775

    CrossRef

  84. 84
    Brian L. Sprague, Amy Trentham-Dietz, Ronald E. Gangnon, Ritesh Ramchandani, John M. Hampton, Stephanie A. Robert, Patrick L. Remington, Polly A. Newcomb, Socioeconomic status and survival after an invasive breast cancer diagnosis, Cancer, 2011, 117, 7
    Direct Link:
  85. 85
    Jane Wang, Tiffany Ting-Fang Shih, Ruoh-Fang Yen, Yen-Shen Lu, Chin-Yu Chen, Tsui-Lien Mao, Ching-Hung Lin, Wen-Hung Kuo, Yuh-Show Tsai, King-Jen Chang, Kuo-Liong Chien, The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer, Academic Radiology, 2011, 18, 2, 212

    CrossRef

  86. 86
    Dabei Tang, Shanqi Xu, Qingyuan Zhang, Wenhui Zhao, The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer, Medical Oncology, 2011,

    CrossRef

  87. 87
    Enja J. Bantema-Joppe, Hans Paul van der Laan, Geertruida H. de Bock, Robin Wijsman, Wil V. Dolsma, Dianne M. Busz, Johannes A. Langendijk, John H. Maduro, Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival, Radiotherapy and Oncology, 2011, 100, 2, 215

    CrossRef

  88. 88
    Venkateswaran Subramaniam, Olga Ace, Gerald J. Prud'homme, Serge Jothy, Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells, Experimental and Molecular Pathology, 2011, 90, 1, 116

    CrossRef

  89. 89
    Xin Zhou, Triple negative breast cancer: 5 years follow-up, The Chinese-German Journal of Clinical Oncology, 2011, 10, 6, 317

    CrossRef

  90. 90
    Hiroko Kawashima, Masafumi Inokuchi, Hiroyuki Furukawa, Seiko Kitamura, Triple-negative Breast Cancer, Academic Radiology, 2011, 18, 8, 963

    CrossRef

  91. 91
    Stephen Dyar, Alvaro Moreno-Aspitia, Triple-negative breast cancer and new treatment developments, Clinical Investigation, 2011, 1, 8, 1107

    CrossRef

  92. 92
    Farrell C. Adkins, Ana Maria Gonzalez-Angulo, Xiudong Lei, Leonel F. Hernandez-Aya, Elizabeth A. Mittendorf, Jennifer K. Litton, Jamie Wagner, Kelly K. Hunt, Wendy A. Woodward, Funda Meric-Bernstam, Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation, Annals of Surgical Oncology, 2011, 18, 11, 3164

    CrossRef

  93. 93
    Anna Niwińska, Wojciech Olszewski, Magdalena Murawska, Katarzyna Pogoda, Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes, Journal of Neuro-Oncology, 2011, 105, 3, 547

    CrossRef

  94. 94
    Ayca Gucalp, Tiffany A. Traina, Triple-Negative Breast Cancer: Adjuvant Therapeutic Options, Chemotherapy Research and Practice, 2011, 2011, 1

    CrossRef

  95. 95
    Shu-Lian Wang, Ye-Xiong Li, Yong-Wen Song, Wei-Hu Wang, Jing Jin, Yue-Ping Liu, Xin-Fan Liu, Zi-Hao Yu, Triple-Negative or HER2-Positive Status Predicts Higher Rates of Locoregional Recurrence in Node-Positive Breast Cancer Patients After Mastectomy, International Journal of Radiation Oncology*Biology*Physics, 2011, 80, 4, 1095

    CrossRef

  96. 96
    Fernando Lara-Medina, Víctor Pérez-Sánchez, David Saavedra-Pérez, Monika Blake-Cerda, Claudia Arce, Daniel Motola-Kuba, Cynthia Villarreal-Garza, Ana Maria González-Angulo, Enrique Bargalló, Jose Luis Aguilar, Alejandro Mohar, Óscar Arrieta, Triple-negative breast cancer in Hispanic patients, Cancer, 2011, 117, 16
    Direct Link:
  97. 97
    Yoon Jung Choi, Min Hyun Seong, Seon Hyeong Choi, Shin Ho Kook, Hyon Joo Kwag, Yong Lai Park, Chan Heun Park, Ultrasound and Clinicopathological Characteristics of Triple Receptor-Negative Breast Cancers, Journal of Breast Cancer, 2011, 14, 2, 119

    CrossRef

  98. 98
    Sarah Barton, Nicholas C. Turner, Handbook of Metastatic Breast Cancer, 2011,

    CrossRef

  99. 99
    Mary Jo Lund, Ebonee N. Butler, Brionna Y. Hair, Kevin C. Ward, Judy H. Andrews, Gabriella Oprea-Ilies, A. Rana Bayakly, Ruth M. O'Regan, Paula M. Vertino, J. William Eley, Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes, Cancer, 2010, 116, 11
    Direct Link:
  100. 100
    K.A. Dookeran, Age/Race Differences in HER2 Testing and in Incidence Rates for Breast Cancer Triple Subtypes: A Population-Based Study and First Report, Breast Diseases: A Year Book Quarterly, 2010, 21, 4, 338

    CrossRef

  101. 101
    Melinda L. Telli, Ellen T. Chang, Allison W. Kurian, Theresa H. M. Keegan, Laura A. McClure, Daphne Lichtensztajn, James M. Ford, Scarlett L. Gomez, Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry, Breast Cancer Research and Treatment, 2010, 127, 2, 471

    CrossRef

  102. 102
    Sunil Badve, David J Dabbs, Stuart J Schnitt, Frederick L Baehner, Thomas Decker, Vincenzo Eusebi, Stephen B Fox, Shu Ichihara, Jocelyne Jacquemier, Sunil R Lakhani, José Palacios, Emad A Rakha, Andrea L Richardson, Fernando C Schmitt, Puay-Hoon Tan, Gary M Tse, Britta Weigelt, Ian O Ellis, Jorge S Reis-Filho, Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists, Modern Pathology, 2010, 24, 2, 157

    CrossRef

  103. 103
    Sandro Barni, Mary Cabiddu, Fausto Petrelli, Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls, Expert Review of Anticancer Therapy, 2010, 10, 2, 185

    CrossRef

  104. 104
    Anastasia Constantinidou, Robin L Jones, Jorge S Reis-Filho, Beyond triple-negative breast cancer: the need to define new subtypes, Expert Review of Anticancer Therapy, 2010, 10, 8, 1197

    CrossRef

  105. 105
    U. Hüttemann, E. Langer, A. Schönherr, K. Zwiefel, M. Neumann, W. Janni, S. Mohrmann, BRCA-Aktivität beim triple-negativen Mammakarzinom, Der Gynäkologe, 2010, 43, 12, 1002

    CrossRef

  106. 106
    Lobna R. Ezz Elarab, Manal Mahdy, Khaled Abdel Karim, BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel, The Chinese-German Journal of Clinical Oncology, 2010, 9, 12, 700

    CrossRef

  107. 107
    Colin Mooney, Sofia Merajver, Breast cancer screening recommendations: dynamic extrapolation of limited data, Breast Cancer Research and Treatment, 2010, 121, 1, 143

    CrossRef

  108. 108
    Helen M. Heneghan, Nicola Miller, Aoife J. Lowery, Karl J. Sweeney, John Newell, Michael J. Kerin, Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer, Annals of Surgery, 2010, 251, 3, 499

    CrossRef

  109. 109
    Xi-ru Li, Mei Liu, Yan-jun Zhang, Jian-dong Wang, Yi-qiong Zheng, Jie Li, Bing Ma, Xin Song, CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients, Medical Oncology, 2010, 28, S1, 129

    CrossRef

  110. 110
    Lin Sun, Lin Zhang, Shasha Ren, Deding Tao, Yaqun Wu, Clinicopathologic features and related prognosis factors analysis of the basal and non-basal phenotype of triple negative breast cancer, The Chinese-German Journal of Clinical Oncology, 2010, 9, 5, 249

    CrossRef

  111. 111
    Chhanda Bewtra, Clinicopathologic Features of Female Breast Cancer in Kumasi, Ghana, International Journal of Cancer Research, 2010, 6, 3, 154

    CrossRef

  112. 112
    Xin Zhou, Qian Liu, Clinicopathological characters of triple negative breast cancer, Chinese Journal of Cancer Research, 2010, 22, 1, 17

    CrossRef

  113. 113
    Kyung Keun Lee, Jin Young Kim, Jin Hyang Jung, Ji Young Park, Ho Yong Park, Clinicopathological Feature and Recurrence Pattern of Triple Negative Breast Cancer, Journal of the Korean Surgical Society, 2010, 79, 1, 14

    CrossRef

  114. 114
    Yutaka Yamamoto, Hirotaka Iwase, Clinicopathological features and treatment strategy for triple-negative breast cancer, International Journal of Clinical Oncology, 2010, 15, 4, 341

    CrossRef

  115. 115
    Carol DeSantis, Ahmedin Jemal, Elizabeth Ward, Disparities in breast cancer prognostic factors by race, insurance status, and education, Cancer Causes & Control, 2010, 21, 9, 1445

    CrossRef

  116. 116
    Daixin Yin, Cyllene Morris, Mark Allen, Rosemary Cress, Janet Bates, Lihua Liu, Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups?, Cancer Causes & Control, 2010, 21, 10, 1721

    CrossRef

  117. 117
    Tanya Agurs-Collins, Barbara K. Dunn, Doris Browne, Karen A. Johnson, Ronald Lubet, Epidemiology of Health Disparities in Relation to the Biology of Estrogen Receptor–Negative Breast Cancer, Seminars in Oncology, 2010, 37, 4, 384

    CrossRef

  118. 118
    Lisa Rydén, Karin Jirström, Monica Haglund, Olle Stål, Mårten Fernö, Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up, Breast Cancer Research and Treatment, 2010, 120, 2, 491

    CrossRef

  119. 119
    Cagatay Arslan, Omer Dizdar, Kadri Altundag, Estrogen receptor immunohistochemistry cutoff value: Standardization is needed, Human Pathology, 2010, 41, 1, 150

    CrossRef

  120. 120
    Aldo Reigosa, Ángel Fernández, Daily Gutiérrez, Eduardo Caleiras, David Hardisson, Herbert Espig, Felipe Saldivia, Angeles Juarranz, Francisco Sanz, Expresión de p63 y citoqueratina 5/6 en los diferentes tipos moleculares del carcinoma de mama, Revista Española de Patología, 2010, 43, 2, 79

    CrossRef

  121. 121
    Xu-biao WEI, Cheng-chen HAN, Jing-jing XU, Wei-qiang ZHENG, Expression of ER, PR, HER-2, PCNA and P53 genes in breast cancer patients in Shanghai and the relevant clinical significance, Academic Journal of Second Military Medical University, 2010, 30, 7, 748

    CrossRef

  122. 122
    Amanda I. Phipps, Diana S. M. Buist, Kathleen E. Malone, William E. Barlow, Peggy L. Porter, Karla Kerlikowske, Christopher I. Li, Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk, Breast Cancer Research and Treatment, 2010, 126, 3, 671

    CrossRef

  123. 123
    Barbara K. Dunn, Tanya Agurs-Collins, Doris Browne, Ronald Lubet, Karen A. Johnson, Health disparities in breast cancer: biology meets socioeconomic status, Breast Cancer Research and Treatment, 2010, 121, 2, 281

    CrossRef

  124. 124
    Shivani S. Shinde, Michele R. Forman, Henry M. Kuerer, Kai Yan, Florentia Peintinger, Kelly K. Hunt, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans, Higher parity and shorter breastfeeding duration, Cancer, 2010, 116, 21
    Direct Link:
  125. 125
    Francisco Javier Andreu, Histologic diagnosis in young women with breast cancer, Breast Cancer Research and Treatment, 2010, 123, S1, 15

    CrossRef

  126. 126
    Minoru Miyashita, Takanori Ishida, Kazuyuki Ishida, Kentaro Tamaki, Masakazu Amari, Mika Watanabe, Noriaki Ohuchi, Hironobu Sasano, Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates, Virchows Archiv, 2010, 458, 1, 65

    CrossRef

  127. 127
    Ming Lu, Stephen A. Whelan, Jianbo He, Romaine E. Saxton, Kym F. Faull, Julian P. Whitelegge, Helena R. Chang, Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer, Clinical Proteomics, 2010, 6, 3, 93

    CrossRef

  128. 128
    Mohamed M. Desouki, Shaoxi Liao, Huayi Huang, Jeffrey Conroy, Norma J. Nowak, Lori Shepherd, Daniel P. Gaile, Joseph Geradts, Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach, Journal of Cancer Research and Clinical Oncology, 2010, 137, 5, 795

    CrossRef

  129. 129
    Hiroko Kawashima, Imaging findings of triple-negative breast cancer, Breast Cancer, 2010, 18, 3, 145

    CrossRef

  130. 130
    Ashraf Khan, Otto Walter, IMP3 expression in triple-negative breast carcinoma - Reply, Human Pathology, 2010, 41, 9, 1356

    CrossRef

  131. 131
    S. Kalla Singh, Q.W. Tan, C. Brito, M. De León, D. De León, Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African–American women, Growth Hormone & IGF Research, 2010, 20, 3, 245

    CrossRef

  132. 132
    David P. Rose, Linda Vona-Davis, Interaction between menopausal status and obesity in affecting breast cancer risk, Maturitas, 2010, 66, 1, 33

    CrossRef

  133. 133
    A.A. Kotsori, S. Dolly, A. Sheri, M. Parton, N. Shaunak, S. Ashley, G. Walsh, S. Johnston, I.E. Smith, Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?, Oncology, 2010, 79, 5-6, 331

    CrossRef

  134. 134
    Zhenkun Fu, Mingli Jiao, Mingyan Zhang, Fengyan Xu, Weiguang Yuan, Da Pang, Dianjun Li, LFA-1 gene polymorphisms are associated with the sporadic infiltrative duct breast carcinoma in Chinese Han women of Heilongjiang Province, Breast Cancer Research and Treatment, 2010, 127, 1, 265

    CrossRef

  135. 135
    Catherine Oakman, Giuseppe Viale, Angelo Di Leo, Management of triple negative breast cancer, The Breast, 2010, 19, 5, 312

    CrossRef

  136. 136
    Erinn Downs-Kelly, Michael Z. Gilcrease, Matrix-producing Carcinoma: Just Another Triple-negative Breast Cancer?, The American Journal of Surgical Pathology, 2010, 34, 1, 125

    CrossRef

  137. 137
    Sheng-Xiang Lin, Jiong Chen, Mausumi Mazumdar, Donald Poirier, Cheng Wang, Arezki Azzi, Ming Zhou, Molecular therapy of breast cancer: progress and future directions, Nature Reviews Endocrinology, 2010, 6, 9, 485

    CrossRef

  138. 138
    Keith A. Dookeran, James J. Dignam, Karen Ferrer, Marin Sekosan, Worta McCaskill-Stevens, Sarah Gehlert, p53 as a Marker of Prognosis in African-American Women with Breast Cancer, Annals of Surgical Oncology, 2010, 17, 5, 1398

    CrossRef

  139. 139
    Mariana Chavez-MacGregor, Jennifer Litton, Huiqin Chen, Sharon H. Giordano, Clifford A. Hudis, Antonio C. Wolff, Vicente Valero, Gabriel N. Hortobagyi, Melissa L. Bondy, Ana Maria Gonzalez-Angulo, Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy, Cancer, 2010, 116, 17
    Direct Link:
  140. 140
    L. Staudacher, P. H. Cottu, V. Dieras, A. Vincent-Salomon, M. N. Guilhaume, L. Escalup, T. Dorval, P. Beuzeboc, L. Mignot, J. Y. Pierga, Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience, Annals of Oncology, 2010, 22, 4, 848

    CrossRef

  141. 141
    G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G. Pruneri, P. Veronesi, R. Torrisi, E. Montagna, A. Luini, M. Intra, O. Gentilini, R. Ghisini, A. Goldhirsch, M. Colleoni, Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer, Annals of Oncology, 2010, 21, 10, 1974

    CrossRef

  142. 142
    B.M. Beadle, Relationship Between Age and Axillary Lymph Node Involvement in Women With Breast Cancer, Breast Diseases: A Year Book Quarterly, 2010, 21, 3, 223

    CrossRef

  143. 143
    Hongbo Lu, Xiaodong Xie, Zhaozhe Liu, Research progress in triple-negative breast cancer, The Chinese-German Journal of Clinical Oncology, 2010, 9, 4, 239

    CrossRef

  144. 144
    Richard B. Wilder, Lisa D. Curcio, Rajesh K. Khanijou, Martin E. Eisner, Jane L. Kakkis, Lucy Chittenden, Jeffrey Agustin, Jessica Lizarde, Albert V. Mesa, Jorge C. Macedo, John Ravera, Kenneth M. Tokita, Results With Accelerated Partial Breast Irradiation in Terms of Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor 2 Status, International Journal of Radiation Oncology*Biology*Physics, 2010, 78, 3, 799

    CrossRef

  145. 145
    S Kashiwagi, M Yashiro, T Takashima, S Nomura, S Noda, H Kawajiri, T Ishikawa, K Wakasa, K Hirakawa, Significance of E-cadherin expression in triple-negative breast cancer, British Journal of Cancer, 2010, 103, 2, 249

    CrossRef

  146. 146
    Sarah Gehlert, Ann Murray, Dana Sohmer, Martha McClintock, Suzanne Conzen, Olufunmilayo Olopade, The Importance of Transdisciplinary Collaborations for Understanding and Resolving Health Disparities, Social Work in Public Health, 2010, 25, 3-4, 408

    CrossRef

  147. 147
    Xiao Wang, Lan Chao, Liansheng Chen, Guohui Ma, Guangchao Jin, Mei Hua, Gengyin Zhou, The Mammographic Correlations with Basal-Like Phenotype of Invasive Breast Cancer, Academic Radiology, 2010, 17, 3, 333

    CrossRef

  148. 148
    Rajul Kothari, Carl Morrison, Debra Richardson, Shelly Seward, David O'Malley, Larry Copeland, Jeffrey Fowler, David E. Cohn, The prognostic significance of the triple negative phenotype in endometrial cancer, Gynecologic Oncology, 2010, 118, 2, 172

    CrossRef

  149. 149
    Alison H. Trainer, Craig R. Lewis, Kathy Tucker, Bettina Meiser, Michael Friedlander, Robyn L. Ward, The role of BRCA mutation testing in determining breast cancer therapy, Nature Reviews Clinical Oncology, 2010, 7, 12, 708

    CrossRef

  150. 150
    Sumanta Kumar Pal, Barrett H. Childs, Mark Pegram, Triple negative breast cancer: unmet medical needs, Breast Cancer Research and Treatment, 2010, 125, 3, 627

    CrossRef

  151. 151
    William D. Foulkes, Ian E. Smith, Jorge S. Reis-Filho, Triple-Negative Breast Cancer, New England Journal of Medicine, 2010, 363, 20, 1938

    CrossRef

  152. 152
    Anthony D. Elias, Triple-Negative Breast Cancer, American Journal of Clinical Oncology, 2010, 33, 6, 637

    CrossRef

  153. 153
    Shaheenah Dawood, Triple-Negative Breast Cancer, Drugs, 2010, 70, 17, 2247

    CrossRef

  154. 154
    Darrel W. Cleere, Triple-negative breast cancer: a clinical update, Community Oncology, 2010, 7, 5, 203

    CrossRef

  155. 155
    Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni, Triple-negative breast cancer: disease entity or title of convenience?, Nature Reviews Clinical Oncology, 2010, 7, 12, 683

    CrossRef

  156. 156
    Franca Podo, Lutgarde M.C. Buydens, Hadassa Degani, Riet Hilhorst, Edda Klipp, Ingrid S. Gribbestad, Sabine Van Huffel, Hanneke W.M. van Laarhoven, Jan Luts, Daniel Monleon, Geert J. Postma, Nicole Schneiderhan-Marra, Filippo Santoro, Hans Wouters, Hege G. Russnes, Therese Sørlie, Elda Tagliabue, Anne-Lise Børresen-Dale, Triple-negative breast cancer: Present challenges and new perspectives, Molecular Oncology, 2010, 4, 3, 209

    CrossRef

  157. 157
    Mandira Ray, Blase N. Polite, Triple-Negative Breast Cancers, The Cancer Journal, 2010, 16, 1, 17

    CrossRef

  158. 158
    Ramachandran Venkitaraman, Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features, Expert Review of Anticancer Therapy, 2010, 10, 2, 199

    CrossRef

  159. 159
    Esther M. Kruijf, Johanna G. H. Nes, Cornelis J. H. Velde, Hein Putter, Vincent T. H. B. M. Smit, Gerrit Jan Liefers, Peter J. K. Kuppen, Rob A. E. M. Tollenaar, Wilma E. Mesker, Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients, Breast Cancer Research and Treatment, 2010, 125, 3, 687

    CrossRef

  160. 160
    Pierre Heudel, Sebastien Cimarelli, Anthony Montella, Catherine Bouteille, Thomas Mognetti, Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors, International Journal of Clinical Oncology, 2010, 15, 6, 588

    CrossRef

  161. 161
    Carol A. Parise, Katrina R. Bauer, Vincent Caggiano, Variation in breast cancer subtypes with age and race/ethnicity, Critical Reviews in Oncology/Hematology, 2010, 76, 1, 44

    CrossRef

  162. 162
    Andrey I. Khramtsov, Galina F. Khramtsova, Maria Tretiakova, Dezheng Huo, Olufunmilayo I. Olopade, Kathleen H. Goss, Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome, The American Journal of Pathology, 2010, 176, 6, 2911

    CrossRef

  163. 163
    Katelyn P. Mack, Joanne Pavao, Farzaneh Tabnak, Kirsten Knutson, Rachel Kimerling, Adherence to Recent Screening Mammography among Latinas: Findings from the California Women's Health Survey, Journal of Women's Health, 2009, 18, 3, 347

    CrossRef

  164. 164
    Zhenkun Fu, Dalin Li, Wei Jiang, Lihong Wang, Jie Zhang, Fengyan Xu, Da Pang, Dianjun Li, Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province, Breast Cancer Research and Treatment, 2009, 120, 1, 195

    CrossRef

  165. 165
    A. Spitale, P. Mazzola, D. Soldini, L. Mazzucchelli, A. Bordoni, Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland, Annals of Oncology, 2009, 20, 4, 628

    CrossRef

  166. 166
    John T. Vetto, Shiuh Wen Luoh, Arpana Naik, Breast Cancer in Premenopausal Women, Current Problems in Surgery, 2009, 46, 12, 944

    CrossRef

  167. 167
    Anselm J. Hennis, Ian R. Hambleton, Suh-Yuh Wu, Maria Cristina Leske, Barbara Nemesure, Breast cancer incidence and mortality in a Caribbean population: Comparisons with African-Americans, International Journal of Cancer, 2009, 124, 2
    Direct Link:
  168. 168
    R H Jack, E A Davies, H Møller, Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England, British Journal of Cancer, 2009, 100, 3, 545

    CrossRef

  169. 169
    Kathryn E. Huber, Lisa A. Carey, David E. Wazer, Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy, Seminars in Radiation Oncology, 2009, 19, 4, 204

    CrossRef

  170. 170
    Carol A. Parise, Katrina R. Bauer, Monica M. Brown, Vincent Caggiano, Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004, The Breast Journal, 2009, 15, 6
    Direct Link:
  171. 171
    Sabine C. Linn, Laura J. Van 't Veer, Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept, European Journal of Cancer, 2009, 45, 11

    CrossRef

  172. 172
    Yutaka Yamamoto, Mutsuko Ibusuki, Masahiro Nakano, Teru Kawasoe, Ryousuke Hiki, Hirotaka Iwase, Clinical significance of basal-like subtype in triple-negative breast cancer, Breast Cancer, 2009, 16, 4, 260

    CrossRef

  173. 173
    Jae Seok Ahn, Jihyoung Cho, Sun Young Kwon, Sun Hee Kang, Clinicopathologic Characteristics and Prognosis of Early Stage Triple Negative Breast Cancer: Comparison with Non-triple Negative Group, Journal of the Korean Surgical Society, 2009, 77, 1, 37

    CrossRef

  174. 174
    Hirotaka Iwase, Junichi Kurebayashi, Hitoshi Tsuda, Tomohiko Ohta, Masafumi Kurosumi, Kazuaki Miyamoto, Yutaka Yamamoto, Takuji Iwase, Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society, Breast Cancer, 2009, 17, 2, 118

    CrossRef

  175. 175
    Dalal M. Al-Tamimi, Philip S. Bernard, Mohamed A. Shawarby, Ali M. Al-Amri, Maha Abdel Hadi, Distribution of Molecular Breast Cancer Subtypes in Middle Eastern-Saudi Arabian Women: A Pilot Study, Ultrastructural Pathology, 2009, 33, 4, 141

    CrossRef

  176. 176
    F. McKenzie, M. Jeffreys, Do Lifestyle or Social Factors Explain Ethnic/Racial Inequalities in Breast Cancer Survival?, Epidemiologic Reviews, 2009, 31, 1, 52

    CrossRef

  177. 177
    Anthony Gonçalves, Mathilde Deblock, Benjamin Esterni, Carole Tarpin, François Bertucci, Marine Gilabert, Emmanuelle Charafe-Jauffret, Jocelyne Jacquemier, Gilles Houvenaeghel, Jean-Marc Extra, Patrice Viens, Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status, Anti-Cancer Drugs, 2009, 20, 10, 946

    CrossRef

  178. 178
    B. Corkery, J. Crown, M. Clynes, N. O'Donovan, Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer, Annals of Oncology, 2009, 20, 5, 862

    CrossRef

  179. 179
    David P Rose, Linda Vona-Davis, Influence of obesity on breast cancer receptor status and prognosis, Expert Review of Anticancer Therapy, 2009, 9, 8, 1091

    CrossRef

  180. 180
    Ping Tang, Kristin A. Skinner, David G. Hicks, Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis, Diagnostic Molecular Pathology, 2009, 18, 3, 125

    CrossRef

  181. 181
    T.H. Oude Munnink, W.B. Nagengast, A.H. Brouwers, C.P. Schröder, G.A. Hospers, M.N. Lub-de Hooge, E. van der Wall, P.J. van Diest, E.G.E. de Vries, Molecular imaging of breast cancer, The Breast, 2009, 18, S66

    CrossRef

  182. 182
    Hans-Peter Sinn, Molekulare Pathologie beim Mammakarzinom, Onkopipeline, 2009, 2, 4, 141

    CrossRef

  183. 183
    Erin F. Gillespie, Melony E. Sorbero, David A. Hanauer, Michael S. Sabel, Emily J. Herrmann, Laura J. Weiser, Christina H. Jagielski, Jennifer J. Griggs, Obesity and Angiolymphatic Invasion in Primary Breast Cancer, Annals of Surgical Oncology, 2009, 17, 3, 752

    CrossRef

  184. 184
    B. J. Chae, J. S. Bae, A. Lee, W. C. Park, Y. J. Seo, B. J. Song, J. S. Kim, S. S. Jung, p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer, Japanese Journal of Clinical Oncology, 2009, 39, 4, 217

    CrossRef

  185. 185
    Junichi Kurebayashi, Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics, Breast Cancer, 2009, 16, 4, 275

    CrossRef

  186. 186
    Jun Mo Kim, Tae Yoon Hwang, Su Hwan Kang, Soo Jung Lee, Young Kyung Bae, Prognostic Significance of Basal Markers in Triple-negative Breast Cancers, Journal of Breast Cancer, 2009, 12, 1, 4

    CrossRef

  187. 187
    Fatma M. Taha, Ahmed A. Zeeneldin, Amani M. Helal, Ayman A. Gaber, Yasser A. Sallam, Hanan Ramadan, Manar M. Moneer, Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer, Clinical Biochemistry, 2009, 42, 13-14, 1420

    CrossRef

  188. 188
    Joan E. Cunningham, Alberto J. Montero, Elizabeth Garrett-Mayer, Hans J. Berkel, Bert Ely, Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status, Cancer Causes & Control, 2009, 21, 3, 399

    CrossRef

  189. 189
    K. S. Albain, J. M. Unger, J. J. Crowley, C. A. Coltman, D. L. Hershman, Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group, JNCI Journal of the National Cancer Institute, 2009, 101, 14, 984

    CrossRef

  190. 190
    Dana E. Rollison, Anna R. Giuliano, Betsy C. Risendal, Carol Sweeney, David Boulware, Christine Laronga, Kathy B. Baumgartner, Tim Byers, Martha L. Slattery, Serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in relation to breast cancer among Hispanic and white, non-Hispanic women in the US Southwest, Breast Cancer Research and Treatment, 2009, 121, 3, 661

    CrossRef

  191. 191
    Jyoti Nautiyal, Pralay Majumder, Bhaumik B. Patel, Francis Y. Lee, Adhip P.N. Majumdar, Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling, Cancer Letters, 2009, 283, 2, 143

    CrossRef

  192. 192
    Henry G. Kaplan, Judith A. Malmgren, Mary Atwood, T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy, The Breast Journal, 2009, 15, 5
    Direct Link:
  193. 193
    Katrina F. Trivers, Mary Jo Lund, Peggy L. Porter, Jonathan M. Liff, Elaine W. Flagg, Ralph J. Coates, J. William Eley, The epidemiology of triple-negative breast cancer, including race, Cancer Causes & Control, 2009, 20, 7, 1071

    CrossRef

  194. 194
    Linda Vona-Davis, David P. Rose, The Influence of Socioeconomic Disparities on Breast Cancer Tumor Biology and Prognosis: A Review, Journal of Women's Health, 2009, 18, 6, 883

    CrossRef

  195. 195
    H. Zhang, E. A. Rakha, G. R. Ball, I. Spiteri, M. Aleskandarany, E. C. Paish, D. G. Powe, R. D. Macmillan, C. Caldas, I. O. Ellis, A. R. Green, The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer, Breast Cancer Research and Treatment, 2009, 121, 1, 41

    CrossRef

  196. 196
    Janneke E. Jaspers, Sven Rottenberg, Jos Jonkers, Therapeutic options for triple-negative breast cancers with defective homologous recombination, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009, 1796, 2, 266

    CrossRef

  197. 197
    S.J. Dawson, E. Provenzano, C. Caldas, Triple negative breast cancers: Clinical and prognostic implications, European Journal of Cancer, 2009, 45, 27

    CrossRef

  198. 198
    O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck, Triple-negative breast cancer--current status and future directions, Annals of Oncology, 2009, 20, 12, 1913

    CrossRef

  199. 199
    Aye Aye Thike, Poh Yian Cheok, Ana Richelia Jara-Lazaro, Benita Tan, Patrick Tan, Puay Hoon Tan, Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer, Modern Pathology, 2009, 23, 1, 123

    CrossRef

  200. 200
    Eun Sook Ko, Byung Hee Lee, Hyun-A Kim, Woo-Chul Noh, Min Suk Kim, Sang-Ah Lee, Triple-negative breast cancer: correlation between imaging and pathological findings, European Radiology, 2009, 20, 5, 1111

    CrossRef

  201. 201
    PierFranco Conte, Valentina Guarneri, Triple-negative breast cancer: current management and future options, European Journal of Cancer Supplements, 2009, 7, 1, 14

    CrossRef

  202. 202
    Chad A. Livasy, Triple-Negative Breast Carcinoma, Surgical Pathology Clinics, 2009, 2, 2, 247

    CrossRef

  203. 203
    Daron J. Williams, Cynthia Cohen, Ta Van To, Andrew J. Page, Diane Lawson, Zachary M. Sussman, Aziza Nassar, Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray, Human Pathology, 2009, 40, 8, 1176

    CrossRef

  204. 204
    Monica Brown, Katrina Bauer, Mary Pare, Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004, Breast Cancer Research and Treatment, 2009, 120, 1, 217

    CrossRef

  205. 205
    L.S. Kilburn, ‘Triple Negative’ Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials, Clinical Oncology, 2008, 20, 1, 35

    CrossRef

  206. 206
    Chukwuemeka U. Ihemelandu, Tammey J. Naab, Haile M. Mezghebe, Kepher H. Makambi, Suryanarayana M. Siram, LaSalle D. Leffall, Robert L. DeWitty, Wayne A. Frederick, Basal cell–like (triple-negative) breast cancer, a predictor of distant metastasis in African American women, The American Journal of Surgery, 2008, 195, 2, 153

    CrossRef

  207. 207
    Rita Bori, Gábor Cserni, Basal Phenotype in Breast Carcinoma Occurring in Women Aged 35 or Younger, Pathology & Oncology Research, 2008, 15, 1, 41

    CrossRef

  208. 208
    Ezzeldin Ibrahim, Aboelkhair M. Al-Gahmi, Ahmed A. Zeenelin, Jamal M. Zekri, Tawfik R. Elkhodary, Hussein E. Gaballa, Ehab E. Fawzy, Mohamed E. El sayed, Mohamed S. Alzahrani, Basal vs. luminal a breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers, Medical Oncology, 2008, 26, 3, 372

    CrossRef

  209. 209
    Bing Wei, Jianmin Wang, Patricia Bourne, Qi Yang, David Hicks, Hong Bu, Ping Tang, Bone metastasis is strongly associated with estrogen receptor–positive/progesterone receptor–negative breast carcinomas, Human Pathology, 2008, 39, 12, 1809

    CrossRef

  210. 210
    Tuya Pal, Susan Vadaparampil, Judy Betts, Cheryl Miree, Song Li, Steven A. Narod, BRCA1/2in High-Risk African American Women with Breast Cancer: Providing Genetic Testing through Various Recruitment Strategies, Genetic Testing, 2008, 12, 3, 401

    CrossRef

  211. 211
    S E Elsheikh, A R Green, E A Rakha, R M Samaka, A A Ammar, D Powe, J S Reis-Filho, I O Ellis, Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype, British Journal of Cancer, 2008, 99, 2, 327

    CrossRef

  212. 212
    S. L. Hines, L. A. Vallow, W. W. Tan, R. B. McNeil, E. A. Perez, A. Jain, Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer, Annals of Oncology, 2008, 19, 9, 1561

    CrossRef

  213. 213
    Wen-Jin Yin, Jin-Song Lu, Gen-Hong Di, Yan-Ping Lin, Li-Heng Zhou, Guang-Yu Liu, Jiong Wu, Kun-Wei Shen, Qi-Xia Han, Zhen-Zhou Shen, Zhi-Ming Shao, Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients, Breast Cancer Research and Treatment, 2008, 115, 2, 325

    CrossRef

  214. 214
    Mary Jo B. Lund, Ebonee N. Butler, Harvey L. Bumpers, Joel Okoli, Monica Rizzo, Nadjo Hatchett, Victoria L. Green, Otis W. Brawley, Gabriela M. Oprea-Ilies, Sheryl G. A. Gabram, High prevalence of triple-negative tumors in an urban cancer center, Cancer, 2008, 113, 3
    Direct Link:
  215. 215
    W. F. Anderson, S. Luo, N. Chatterjee, P. S. Rosenberg, R. K. Matsuno, M. T. Goodman, B. Y. Hernandez, M. Reichman, M. P. Dolled-Filhart, R. M. O’Regan, M. Garcia-Closas, C. M. Perou, I. Jatoi, R. W. Cartun, M. E. Sherman, Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program, Breast Cancer Research and Treatment, 2008, 113, 1, 189

    CrossRef

  216. 216
    Reiki Nishimura, Nobuyuki Arima, Is triple negative a prognostic factor in breast cancer?, Breast Cancer, 2008, 15, 4, 303

    CrossRef

  217. 217
    Meena S. Moran, Qifeng Yang, Lyndsay N. Harris, Beth Jones, David P. Tuck, Bruce G. Haffty, Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer, Cancer, 2008, 113, 9
    Direct Link:
  218. 218
    Ping Tang, Jianmin Wang, Patria Bourne, Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?, Human Pathology, 2008, 39, 4, 506

    CrossRef

  219. 219
    Alfredo A. Santillan, John V. Kiluk, John M. Cox, Tammi L. Meade, Nathon Allred, Daniel Ramos, Jeff King, Charles E. Cox, Outcomes of Locoregional Recurrence after Surgical Chest Wall Resection and Reconstruction for Breast Cancer, Annals of Surgical Oncology, 2008, 15, 5, 1322

    CrossRef

  220. 220
    B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, I. E. Smith, Platinum-based chemotherapy in triple-negative breast cancer, Annals of Oncology, 2008, 19, 11, 1847

    CrossRef

  221. 221
    Laura Fejerman, Elad Ziv, Population differences in breast cancer severity, Pharmacogenomics, 2008, 9, 3, 323

    CrossRef

  222. 222
    Mary Jo Lund, Katrina F. Trivers, Peggy L. Porter, Ralph J. Coates, Brian Leyland-Jones, Otis W. Brawley, Elaine W. Flagg, Ruth M. O’Regan, Sheryl G. A. Gabram, J. William Eley, Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA, Breast Cancer Research and Treatment, 2008, 113, 2, 357

    CrossRef

  223. 223
    K.A. Dookeran, Racial and Ethnic Differences in Breast Cancer Survival: How Much Is Explained by Screening, Tumor Severity, Biology, Treatment, Comorbidities, and Demographics?, Breast Diseases: A Year Book Quarterly, 2008, 19, 2, 133

    CrossRef

  224. 224
    L. A. Brinton, M. E. Sherman, J. D. Carreon, W. F. Anderson, Recent Trends in Breast Cancer Among Younger Women in the United States, JNCI Journal of the National Cancer Institute, 2008, 100, 22, 1643

    CrossRef

  225. 225
    Amanda I. Phipps, Kathleen E. Malone, Peggy L. Porter, Janet R. Daling, Christopher I. Li, Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer, Cancer, 2008, 113, 7
    Direct Link:
  226. 226
    April F. Eichler, Irene Kuter, Paula Ryan, Lidia Schapira, Jerry Younger, John W. Henson, Survival in patients with brain metastases from breast cancer, Cancer, 2008, 112, 11
    Direct Link:
  227. 227
    Monica Brown, Alex Tsodikov, Katrina R. Bauer, Carol A. Parise, Vincent Caggiano, The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004, Cancer, 2008, 112, 4
    Direct Link:
  228. 228
    Soonmo Peter Kang, Maritza Martel, Lyndsay N Harris, Triple negative breast cancer: current understanding of biology and treatment options, Current Opinion in Obstetrics and Gynecology, 2008, 20, 1, 40

    CrossRef

  229. You have free access to this content229
    J S Reis-Filho, A N J Tutt, Triple negative tumours: a critical review, Histopathology, 2008, 52, 1
    Direct Link:
  230. 230
    Frank Köster, Jörg B. Engel, Andrew V. Schally, Arnd Hönig, Andreas Schröer, Stephan Seitz, Florian Hohla, Olaf Ortmann, Klaus Diedrich, Stefan Buchholz, Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition, Breast Cancer Research and Treatment, 2008, 116, 2, 273

    CrossRef

  231. You have free access to this content231
    Robert M.W. Hofstra, Amanda B. Spurdle, Diana Eccles, William D. Foulkes, Niels de Wind, Nicoline Hoogerbrugge, Frans B.L. Hogervorst, Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance, Human Mutation, 2008, 29, 11
    Direct Link:
  232. 232
    William J. Irvin, Lisa A. Carey, What is triple-negative breast cancer?, European Journal of Cancer, 2008, 44, 18, 2799

    CrossRef

  233. 233
    Laura J Esserman, Yiwey Shieh, John W Park, Elissa M Ozanne, A role for biomarkers in the screening and diagnosis of breast cancer in younger women, Expert Review of Molecular Diagnostics, 2007, 7, 5, 533

    CrossRef

  234. 234
    Robert C. Millikan, Beth Newman, Chiu-Kit Tse, Patricia G. Moorman, Kathleen Conway, Lisa V. Smith, Miriam H. Labbok, Joseph Geradts, Jeannette T. Bensen, Susan Jackson, Sarah Nyante, Chad Livasy, Lisa Carey, H. Shelton Earp, Charles M. Perou, Epidemiology of basal-like breast cancer, Breast Cancer Research and Treatment, 2007, 109, 1, 123

    CrossRef

  235. 235
    Angelo Sidoni, Fabio Cartaginese, Mariantonietta Colozza, Stefania Gori, Lucio Crinó, ERCC1 expression in triple negative breast carcinoma: the paradox revisited, Breast Cancer Research and Treatment, 2007, 111, 3, 569

    CrossRef

  236. 236
    Wei-Tse Yang, Mark Dryden, Kristine Broglio, Michael Gilcrease, Shaheenah Dawood, Peter J. Dempsey, Vicente Valero, Gabriel Hortobagyi, Deann Atchley, Banu Arun, Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women, Breast Cancer Research and Treatment, 2007, 111, 3, 405

    CrossRef

  237. 237
    David S. P. Tan, Caterina Marchió, Robin L. Jones, Kay Savage, Ian E. Smith, Mitch Dowsett, Jorge S. Reis-Filho, Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients, Breast Cancer Research and Treatment, 2007, 111, 1, 27

    CrossRef

View Full Article (HTML) Get PDF (147K)